{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:25:20Z","timestamp":1790900720974,"version":"4.1.0"},"reference-count":44,"publisher":"EDP Sciences","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1051\/medsci\/200925121039","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T10:02:37Z","timestamp":1299146557000},"page":"1039-1045","source":"Crossref","is-referenced-by-count":10,"title":["Les anticorps radiomarqu\u00e9s pour le traitement des cancers"],"prefix":"10.1051","volume":"25","author":[{"given":"Jacques","family":"Barbet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Chatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"R1","unstructured":"Sisson J, Shapiro B, Beierwaltes WH,et al.Treatment of malignant pheochromocytoma with a new radiopharmaceutical.Trans Assoc Am Physicians1983; 96 : 209\u201317."},{"key":"R2","unstructured":"Suresh C, Srivastava L. Investigators review potential of antibodies in cancer detection and therapy.J Nucl Med1987; 28 : 143\u20137."},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Buchegger F, Press OW, Delaloye AB, Ketterer N. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.Oncologist2008; 13 : 657\u201367.","DOI":"10.1634\/theoncologist.2008-0020"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Bellet D, Dangles-Marie V. Anticorps humanis\u00e9s en th\u00e9rapeutique.Med Sci (Paris)2005; 21 : 1054\u201362","DOI":"10.1051\/medsci\/200521121054"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma : a paradigm for other malignancies ?Cancer Biother Radiopharm2008; 23 : 383\u201397.","DOI":"10.1089\/cbr.2007.0523-U"},{"key":"R6","unstructured":"Horning SJ. Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas.Semin Oncol1993; 20 : 75\u201388."},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma.N Engl J Med2008; 359 : 613\u201326.","DOI":"10.1056\/NEJMra0708875"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies.Curr Opin Hematol2007; 14 : 632\u20138.","DOI":"10.1097\/MOH.0b013e3282efb17c"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.Semin Hematol2008; 45 : 118\u201325.","DOI":"10.1053\/j.seminhematol.2008.02.002"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Chatal JF, Kraeber-Bod\u00e9r\u00e9 F, Barbet J. Consolidation radioimmunotherapy of follicular lymphoma : a step towards cure ?Eur J Nucl Med Mol Imaging2008; 35 : 1236\u20139.","DOI":"10.1007\/s00259-008-0727-z"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Radford J, Van Hoof A,et al.Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol2008; 26 : 5156\u201364.","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Bodet-Milin C, Kraeber-Bod\u00e9r\u00e9 F, Dupas B,et al.Evaluation of response to fractionated radioimmunotherapy with90Y-epratuzumab in non-Hodgkin\u2019s lymphoma by18F-fluorodeoxyglucose positron emission tomography.Haematologica2008; 93 : 390\u20137.","DOI":"10.3324\/haematol.10591"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Ivanov A, Swann R, Illidge T. New insights into the mechanisms of action of radioimmunotherapy in lymphoma.J Pharm Pharmacol2008; 60 : 987\u201398.","DOI":"10.1211\/jpp.60.8.0006"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Wheldon TE. The radiobiological basis of total body irradiation.Br J Radiol1997; 70 : 1204\u20137.","DOI":"10.1259\/bjr.70.840.9505837"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Sharkey RM, Karacay H, Chang CH,et al.Improved therapy of non-Hodgkin\u2019s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.Leukemia2005; 19 : 1064\u20139.","DOI":"10.1038\/sj.leu.2403751"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Press OW, Corcoran M, Subbiah K,et al.A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.Blood2001; 98 : 2535\u201343.","DOI":"10.1182\/blood.V98.8.2535"},{"key":"R17","unstructured":"Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen.Cancer Res1981; 41 : 4354\u201360."},{"key":"R18","unstructured":"Sharkey RM, Pykett MJ, Siegel JA,et al.Radioimmunotherapy of the GW-39 human colonic tumor xenograft with131I-labeled murine monoclonal antibody to carcinoembryonic antigen.Cancer Res1987; 47 : 5672\u20137."},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Buchegger F, Vacca A, Carrel S,et al.Radioimmunotherapy of human colon carcinoma by131I-labelled monoclonal anti-CEA antibodies in a nude mouse model.Int J Cancer1988; 41 : 127\u201334.","DOI":"10.1002\/ijc.2910410123"},{"key":"R20","unstructured":"Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.J Nucl Med2005; 46 : S115\u201327."},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Hahn O, Stadler W. Sorafenib.Curr Opin Oncol2006; 18 : 615\u201321.","DOI":"10.1097\/01.cco.0000245316.82391.52"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Brouwers AH, Mulders PF, de Mulder PH,et al.Lack of efficacy of two consecutive treatments of radioimmunotherapy with131I-cG250 in patients with metastasized clear cell renal cell carcinoma.J Clin Oncol2005; 23 : 6540\u20138.","DOI":"10.1200\/JCO.2005.07.732"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Buchegger F, Pfister C, Fournier K,et al.Ablation of human colon carcinoma in nude mice by131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab\u2019)2fragments.J Clin Invest1989; 83 : 1449\u201356.","DOI":"10.1172\/JCI114037"},{"key":"R24","unstructured":"Schlom J, Eggensperger D, Colcher D,et al.Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates.Cancer Res1992; 52 : 1067\u201372."},{"key":"R25","unstructured":"Nilsson FY, Tolmachev V. Affibody molecules : new protein domains for molecular imaging and targeted tumor therapy.Curr Opin Drug Discov Dev2007; 10 : 167\u201375."},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Muyldermans S. Single domain camel antibodies : current status.J Biotechnol2001; 74 : 277\u2013302.","DOI":"10.1016\/S1389-0352(01)00021-6"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Goldenberg DM, Sharkey RM, Paganelli G,et al.Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.J Clin Oncol2006; 24 : 823\u201334.","DOI":"10.1200\/JCO.2005.03.8471"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Chatal JF, Campion L, Kraeber-Bod\u00e9r\u00e9 F,et al.Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy : a collaborative study with the French Endocrine Tumor Group.J Clin Oncol2006; 24 : 1705\u201311.","DOI":"10.1200\/JCO.2005.04.4917"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Behr TM, Liersch T, Greiner-Bechert L,et al.Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.Cancer2002; 94 : 1373\u201381.","DOI":"10.1002\/cncr.10308"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Liersch T, Meller J, Bittrich M,et al.Update of carcinoembryonic antigen radioimmunotherapy with131I-labetuzumab after salvage resection of colorectal liver metastases : comparison of outcome to a contemporaneous control group.Ann Surg Oncol2007; 14 : 2577\u201390.","DOI":"10.1245\/s10434-006-9328-x"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Ychou M, Azria D, Menkarios C,et al.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab\u2019)2after resection of liver metastases from colorectal cancer.Clin Cancer Res2008; 14 : 3487\u201393.","DOI":"10.1158\/1078-0432.CCR-07-4698"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L,et al.Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.J Clin Oncol2004; 22 : 2522\u201331.","DOI":"10.1200\/JCO.2004.09.154"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Bander NH, Milowsky MI, Nanus DM,et al.Phase I trial of177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.J Clin Oncol2005; 23 : 4591\u2013601.","DOI":"10.1200\/JCO.2005.05.160"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy.Eur J Nucl Med Mol Imaging2002; 29 : 821\u201330","DOI":"10.1007\/s00259-001-0724-y"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment : the future is radiant.Bone Marrow Transplant2005; 36 : 1021\u20136.","DOI":"10.1038\/sj.bmt.1705182"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Sievers EL, Appelbaum FR, Spielberger RT,et al.Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy : a phase I study of an anti-CD33 calicheamicin immunoconjugate.Blood1999; 93 : 3678\u201384.","DOI":"10.1182\/blood.V93.11.3678"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Supiot S, Faivre-Chauvet A, Couturier O,et al.Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.Cancer2002; 94 : 1202\u20139.","DOI":"10.1002\/cncr.10286"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity.Cancer2002; 94 : 1215\u201323","DOI":"10.1002\/cncr.10288"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Jurcic JG, Larson SM, Sgouros G,et al.Targeted alpha particle immunotherapy for myeloid leukemia.Blood2002; 100 : 1233\u20139.","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Zalutsky MR, Reardon DA, Akabani G,et al.Clinical experience with alpha-particle emitting 211At : treatment of recurrent brain tumor patients with211At-labeled chimeric antitenascin monoclonal antibody 81C6.J Nucl Med2008; 49 : 30\u20138.","DOI":"10.2967\/jnumed.107.046938"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Roboz GJ, Bennett JM, Coleman M,et al.Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.Leuk Res2007; 31 : 1141\u20134.","DOI":"10.1016\/j.leukres.2006.11.011"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Saphire EO, Parren PW, Pantophlet R,et al.Crystal structure of a neutralizing human IGG against HIV-1 : a template for vaccine design.Science2001; 293 : 1155\u20139","DOI":"10.1126\/science.1061692"},{"key":"R43","unstructured":"Barbet J, Peltier P, Bardet S,et al.Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.J Nucl Med1998, 39, 1172\u20138."},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Flux G, Bardies M, Monsieurs M,et al.The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.Z Med Phys2006; 16 : 47\u201359.","DOI":"10.1078\/0939-3889-00291"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T19:21:10Z","timestamp":1637349670000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":44,"journal-issue":{"issue":"12"},"alternative-id":["medsci20092512p1039"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/200925121039","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}